Fontem US Withdraws FDA Lawsuit and Plans to Refile in Washington, D.C.
Fontem US, a subsidiary of Imperial Tobacco and the manufacturer of Zone nicotine pouches, has announced the voluntary withdrawal of its lawsuit against the U.S. Food and Drug Administration (FDA). Fontem stated that, following a federal court in Texas’s decision to transfer the case to a federal court in South Carolina. The company has decided to terminate the current proceedings and plans to refile the lawsuit in a federal court in Washington, D.C.
Key Highlights
- Fontem US, a subsidiary of Imperial Tobacco, has withdrawn its lawsuit against the FDA and stated that it intends to refile the case in a federal court in Washington, D.C.
- Previously, a federal court in Texas decided to transfer the case from Texas to a federal court in South Carolina.
- Fontem noted that it had requested the case be transferred to Washington, D.C., should the court grant the motion to transfer; however, this request was ultimately not adopted.
- The original lawsuit alleged that the FDA had neither approved nor rejected the relevant PMTA applications for over four years, ultimately issuing a “Refuse to Accept” letter.
Lawsuit Withdrawal Following Court Transfer Decision
March 25, 2026 — According to Law360, Fontem US, a subsidiary of Imperial Tobacco and the manufacturer and distributor of Zone nicotine pouches, has withdrawn its lawsuit against the U.S. Food and Drug Administration (FDA). In the lawsuit, the company had previously accused the FDA of unfairly delaying the review of its applications for market authorization; the company now states that it will refile the lawsuit in a federal court in Washington, D.C.
Fontem Ends Case and Challenges Venue Decision
Fontem voluntarily ended the lawsuit it had initiated. In a notice filed with the federal court in South Carolina, the company expressed its dissatisfaction with the decision by U.S. District Judge Mark T. Pittman of the Northern District of Texas to transfer the case out of Texas.
Company Requested Transfer to Washington, D.C.
Fontem stated that it had explicitly requested that. Should the court grant the FDA’s motion to transfer. The case be transferred to the District of Columbia; however, the judge ultimately transferred the case to South Carolina.
Argument for Plaintiff’s Choice of Venue
In its notice. Fontem asserted that a plaintiff’s choice of venue is generally entitled to deference, and that the defendant (the FDA) had neither objected to this principle in its response nor opposed the request to transfer the case to the District of Columbia.
Texas Court Cites Weak Connection to the State
Judge Pittman stated that he struggled to identify any genuine connection between the case and the State of Texas. The judge noted that the sole apparent link to Texas stemmed from OM Investment, a convenience store seeking to sell the products in question and a co-plaintiff alongside Fontem in the case.
Court Highlights Caseload and Jurisdiction Factors
The judge further observed that the U.S. District Court for the Northern District of Texas faces a heavy caseload, with each judge overseeing 522 pending cases, compared to 374 cases per judge in the Middle District of North Carolina. Given that Fontem is headquartered in South Carolina, the judge deemed it more appropriate to transfer the case.
Case Limited to Company-Specific Applications
Judge Pittman stated that the present case does not involve broad rules applicable to a multitude of companies; rather, it pertains solely to Fontem’s own specific applications, and the impact on retailers is “relatively weak and minimal.”
Court Weighs Legal and Practical Considerations
According to the judge’s explanation, the court weighed both private and public interest factors when considering the motion to transfer. The judge noted that, as this is a case brought under the Administrative Procedure Act (APA), factors such as the cost of obtaining evidence, compelling testimony, and securing witness attendance have a neutral impact on the proceedings; however, when considering convenience and the burden on the court, a transfer appeared to be the more reasonable course of action.
Original Lawsuit Focused on FDA Review Delays
Fontem had previously filed a lawsuit alleging that the FDA had stalled the processing of its marketing applications for tobacco products.
Allegations of Four-Year Delay and “Refusal to Accept” Letter
The lawsuit asserts that, although the Tobacco Control Act mandates that the FDA issue a decision either approving or rejecting pre-market tobacco product applications within 180 days, the agency failed to either approve or reject the applications for over four years, ultimately issuing only a “Refusal to Accept” letter.





